WAS and Thrombocytopenia: Further studies are needed to determine whether miR-21 has effects on the release of other constituents of platelets and on leukocytes, given that WASp is predominantly expressed in hematopoietic cells and Wiskott-Aldrich syndrome is characterized by immune deficiency as well as thrombocytopenia (34).